Exploratory Cardiovascular Risk Modeling of Orforglipron Using the PREVENT Equations Compared with the Pooled Cohort Equations: A Post-Hoc Analysis from a Systematic Review and Meta-analysis

High Blood Press Cardiovasc Prev. 2026 Jul 15. doi: 10.1007/s40292-026-00814-4. Online ahead of print.ABSTRACTINTRODUCTION: Orforglipron, an oral non-peptide GLP-1 receptor agonist, improves multiple cardiometabolic risk factors. However, prior modeling used only the 2013 Pooled Cohort Equations (PC

A Adir Alper

Fabry disease cardiomyopathy: Time for a closer heart rhythm monitoring?

Heart Fail Rev. 2026 Jul 16;31(1):86. doi: 10.1007/s10741-026-10657-9.ABSTRACTCardiovascular disease represents the leading cause of death in patients with Anderson-Fabry disease (FD), with sudden cardiac death (SCD) being one of the most frequently reported causes of mortality. However, a significa

G Giacomo Mugnai

A Bayesian framework for longitudinal EHR and genetic discovery

Electronic health records (EHRs) provide rich longitudinal disease histories, but existing methods for analysing these data typically treat diseases in isolation¹ and rarely integrate germline genetics. Here we present ALADYNOULLI, a Bayesian generative framework that jointly models longitudinal EHR

S Sarah M Urbut

An encyclopedia of human enhancer-gene regulatory interactions

Identifying transcriptional enhancers and their target genes is essential for understanding gene regulation and the effect of human genetic variation on disease^(1-6). Here we create and evaluate a resource of more than 92 million enhancer-gene regulatory interactions across 1,458 biosamples coverin

A Andreas R Gschwind